Efficacy News and Research

RSS
Study compares efficacy of two treatments for iron overload caused by chronic transfusion therapy

Study compares efficacy of two treatments for iron overload caused by chronic transfusion therapy

Research reveals new standard treatment options for various forms of lymphoma

Research reveals new standard treatment options for various forms of lymphoma

Study provides evidence of acute, long-term safety of external TNS for epilepsy

Study provides evidence of acute, long-term safety of external TNS for epilepsy

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010

SuperGen to present SGI-110 data for MDS, AML at ASH annual meeting

SuperGen to present SGI-110 data for MDS, AML at ASH annual meeting

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Sentara Heart Hospital commences procedures in AtriCure DEEP AF feasibility trial

Sentara Heart Hospital commences procedures in AtriCure DEEP AF feasibility trial

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

AtriCure initiates enrollment in DEEP AF feasibility trial

AtriCure initiates enrollment in DEEP AF feasibility trial

FDA accepts IND application to initiate human clinical trial to evaluate BNC

FDA accepts IND application to initiate human clinical trial to evaluate BNC

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

Research: Environmental bacteria compromises effectiveness of BCG vaccine

Research: Environmental bacteria compromises effectiveness of BCG vaccine

Emotional, social self-efficacy beliefs may contribute on strengthening major expressions of positive orientation

Emotional, social self-efficacy beliefs may contribute on strengthening major expressions of positive orientation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.